Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Mar;34(3):822-31.
doi: 10.1016/j.neurobiolaging.2012.06.014. Epub 2012 Aug 9.

Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals

Reisa A Sperling  1 , Keith A Johnson, P Murali Doraiswamy, Eric M Reiman, Adam S Fleisher, Marwan N Sabbagh, Carl H Sadowsky, Alan Carpenter, Mat D Davis, Ming Lu, Matthew Flitter, Abhinay D Joshi, Christopher M Clark, Michael Grundman, Mark A Mintun, Daniel M Skovronsky, Michael J Pontecorvo; AV45-A05 Study Group
Affiliations
Clinical Trial

Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals

Reisa A Sperling et al. Neurobiol Aging. 2013 Mar.

Abstract

The objective of this study was to evaluate the relationship of amyloid burden, as assessed by florbetapir F 18 ((18)F-AV-45) amyloid positron emission tomography, and cognition in healthy older control (HC) subjects. Seventy-eight HC subjects were assessed with a brief cognitive test battery and positron emission tomography (PET) imaging with (18)F-AV-45. A standard uptake value ratio was computed for mean data from 6 cortical regions using a whole cerebellum reference region. Scans were also visually rated as amyloid positive or amyloid negative by 3 readers. Higher standard uptake value ratio correlated with lower immediate memory (r = -0.33; p = 0.003) and delayed recall scores (r = -0.25; p = 0.027). Performance on immediate recall was also lower in the visually rated amyloid positive compared with amyloid negative HC (p = 0.04), with a similar trend observed in delayed recall (p = 0.06). These findings support the hypothesis that higher amyloid burden is associated with lower memory performance among clinically normal older subjects. Longitudinal follow-up is ongoing to determine whether (18)F-AV-45 may also predict subsequent cognitive decline.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative amyloid positive (Aβ+) and amyloid negative (Aβ−) clinically normal healthy controls (HC). Images have been fitted to Talairach space with each voxel normalized to the cerebellar reference region.
Figure 2
Figure 2
Wechsler Logical Memory Story A Immediate (left) and Delayed (right) recall scores as a function of mean cortical amyloid (SUVr), in the unadjusted regression analyses.
Figure 3
Figure 3
Wechsler Logical Memory Story A performance compared between amyloid positive (n=8) and amyloid negative (n=32) clinically normal healthy controls ≥ 70 years old. Amyloid positivity was determined by visual rating. Amyloid positive older individuals performed significantly worse on both Immediate (p=0.009) and Delayed (p=0.015) recall measures.
See this image and copyright information in PMC

References

    1. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509–17. - PMC - PubMed
    1. Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032–42. - PMC - PubMed
    1. Bennett D, Schneider J, Arvanitakis Z, Kelly J, Aggarwal N, Shah R, Wilson R. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837–44. - PubMed
    1. Chetelat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain. 2011;134(Pt 3):798–807. - PubMed
    1. Choi S, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, Benedum T, Kilbourn M, Skovronsky D, Kung H. Preclinical properties of 18 F-AV-45: A PET agent for AB plaques in the brain. J Nucl Med. 2009;50:1887–994. - PMC - PubMed

Publication types